Therapeutics News and Research

RSS

Researchers clarify the mechanism by which drugs like Celebrex and Vioxx cause heart problems

Researchers at the University of Pennsylvania School of Medicine have clarified the mechanism by which drugs like Celebrex and Vioxx cause heart problems, in multiple animal models.

18 Apr 2006

Study finds nationwide increase in antipsychotic medications used for children with ADHD

A disturbing nationwide trend has been documented by a researcher at the Monroe Carell Jr. Children's Hospital at Vanderbilt: Doctors are prescribing antipsychotic medicines for children with behavioral problems that are not defined as "psychosis," such as attention deficit hyperactivity disorder (ADHD).

18 Apr 2006

St. John's wort and Echinacea increase activity of enzyme in the liver and intestine

St. John's wort and Echinacea, two widely-used herbal preparations, have been found to increase activity of a specific enzyme in the liver and intestine, an enzyme involved in the metabolization of roughly one in every four pharmaceutical drugs on the market today, reports a clinical pharmacologist at Indiana University School of Medicine.

11 Apr 2006

Biodegradable drug containing nano-particles effective in killing human breast tumors

Research studies, based at the University of Pennsylvania, demonstrate that biodegradable nano-particles containing two potent cancer-fighting drugs are effective in killing human breast tumors.

11 Apr 2006

First human recipients of laboratory-grown organs

The first human recipients of laboratory-grown organs were by Anthony Atala, M.D., director of the Institute for Regenerative Medicine at Wake Forest University School of Medicine. In The Lancet, Atala describes long-term success in children and teenagers who received bladders grown from their own cells.

4 Apr 2006

New mechanism that initiates metastasis

Researchers have known for years that the enzyme MMP-9 plays a key role in the spread of colorectal cancer. Now, scientists at Jefferson Medical College in Philadelphia have found out how the enzyme helps initiate the process, known as metastasis.

4 Apr 2006

Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis

The unchecked activity of a cell signaling pathway crucial in embryonic development and the liver's response to injury leads to liver cancer, researchers from Duke University Medical Center and John Hopkins University School of Medicine have found.

4 Apr 2006

Custom made nanoparticles will transform cancer diagnosis and treatment

Researchers have developed "custom" nanoparticles that promise to provide a more targeted and effective way of delivering anticancer drugs than conventional medications or any of the earlier attempts to fight cancer with nanoparticles.

28 Mar 2006

Gene therapy treatment for brain tumours and infections

In a study published in the March 15 issue of The Journal of Immunology, researchers at Board of Governors' Gene Therapeutics Research Institute at Cedars-Sinai Medical Center have developed a way to overcome immune privilege in the brain to eradicate potentially deadly brain tumors such as glioblastoma multiforme and other types of brain infections.

27 Mar 2006

Carotid stenting beneficial for patients with disease but no symptoms

Results from the largest-ever multi-center U.S. registry on the efficacy of carotid stenting shows that the procedure is safe in patients who are at high risk for standard surgical therapy.

20 Mar 2006

Antibody may reduce or eliminate tumors

San Diego State University researcher Roger Sabbadini has brought scientists one step closer to finding a cure for cancer with the creation of an antibody that hinders the growth of tumors by preventing blood vessel formation.

17 Mar 2006

Tibotec Pharmaceuticals receives NDA for investigational HIV protease inhibitor

Tibotec Pharmaceuticals has announced that the New Drug Application (NDA) for TMC114, an investigational HIV protease inhibitor, has been accepted for priority review by the United States Food and Drug Administration (FDA).

7 Mar 2006

Discovery of compound that reduces hallmark lesions of Alzheimer's disease in mice

Researchers at UC Irvine have found that a new compound not only relieves the cognitive symptoms of Alzheimer's disease, but also reduces the two types of brain lesions that are hallmarks of this devastating disease, thereby blocking its progression.

7 Mar 2006

Data from Novogen inflammatory bowel disease drug Phase I clinical trial shows promise

A recently completed Phase 1 clinical trial of an investigational drug to treat inflammatory bowel disease has demonstrated rapid absorption indicating potential for development as an oral therapy.

6 Mar 2006

Pfizer acquires worldwide rights to Exubera

Pfizer has announced that it has acquired the sanofi-aventis worldwide rights to Exubera (inhaled human insulin). Pfizer received approval last month to market Exubera in the United States and the European Union for the treatment of adults with type 1 and type 2 diabetes.

1 Mar 2006